Complementary action of chemical and electrical synapses to perception

Acknowledgements This study was possible by partial financial support from the following agencies: Fundação Araucária, EPSRC-EP/I032606/1, CNPq No. 441553/2014-1, CAPES No. 17656-12-5 and Science Without Borders Program— Process Nos. 17656125, 99999.010583/2013-00 and 245377/2012-3.Peer reviewedPostprin

Mathematical model of brain tumour with glia-neuron interactions and chemotherapy treatment

Acknowledgements This study was possible by partial financial support from the following Brazilian government agencies: Fundação Araucária, EPSRC-EP/I032606/1 and CNPq, CAPES and Science Without Borders Program Process nos. 17656125, 99999.010583/2013-00 and 245377/2012-3.Peer reviewedPreprin

Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?

publishersversionpublishe

Mutual information rate and bounds for it

The amount of information exchanged per unit of time between two nodes in a dynamical network or between two data sets is a powerful concept for analysing complex systems. This quantity, known as the mutual information rate (MIR), is calculated from the mutual information, which is rigorously defined only for random systems. Moreover, the definition of mutual information is based on probabilities of significant events. This work offers a simple alternative way to calculate the MIR in dynamical (deterministic) networks or between two data sets (not fully deterministic), and to calculate its upper and lower bounds without having to calculate probabilities, but rather in terms of well known and well defined quantities in dynamical systems. As possible applications of our bounds, we study the relationship between synchronisation and the exchange of information in a system of two coupled maps and in experimental networks of coupled oscillators

A Novel BCR-ABL1 Mutation in a Patient with Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) represents the most common genetic subtype of adult ALL (20%-30%) and accounts for approximately 50% of all cases in the elderly. It has been considered the subgroup of ALL with the worst outcome. The introduction of tyrosine kinase inhibitors (TKIs) allows complete hematologic remission virtually in all patients, with improved disease-free survival and overall survival. Nevertheless, the emergence of resistant mutations in BCR-ABL1 may require different TKI strategies to overcome the patient's resistance and disease relapse. Here, we report a Ph+B-ALL case with persistent minimal residual disease (MRD) after treatment with dasatinib. The patient expressed the P190BCR-ABL1 isoform and a novel BCR-ABL1 mutation, p.Y440C. The latter is in the C-terminal lobe of the kinase domain, which likely induces deviations in the protein structure and activity and destabilizes its inactive conformation. The treatment was substituted by bosutinib, which binds to the active conformation of the protein, prior to allogeneic bone marrow transplant to overcome the lack of a complete response to dasatinib. These findings strengthen the importance of BCR-ABL1 mutational screening in Ph+ patients, particularly for those who do not achieve complete molecular remission.info:eu-repo/semantics/publishedVersio

Recurrence-based analysis of barrier breakup in the standard nontwist map

We wish to acknowledge the support: CNPq, CAPES, and FAPESP.Peer reviewedPublisher PD